German Christopher Paul 4
4 · RHYTHM PHARMACEUTICALS, INC. · Filed May 19, 2026
Research Summary
AI-generated summary of this filing
RYTM: Corporate Controller Christopher P. German Exercises Options, Sells Shares
What Happened Christopher P. German, Corporate Controller & CAO of Rhythm Pharmaceuticals (RYTM), exercised stock options for a total of 4,442 shares on May 15, 2026 at strike prices of $56.69, $49.23 and $17.97 (total cash paid $187,313). On the same day he sold 4,643 shares in an open-market transaction for $92.21 per share, generating $428,131. The filing also reports 4,442 option-related dispositions at $0, which are reported in the Form 4 as derivative dispositions (see Key Details).
Key Details
- Transaction date: 2026-05-15; Form 4 filed 2026-05-19 (appears timely).
- Option exercises (acquired):
- 1,687 shares @ $56.69 = $95,636
- 1,349 shares @ $49.23 = $66,411
- 1,406 shares @ $17.97 = $25,266
- Aggregate exercised: 4,442 shares; total cash paid ≈ $187,313.
- Open-market sale (disposed): 4,643 shares @ $92.21 = $428,131.
- Reported derivative dispositions at $0 for the same three option lots (1,687; 1,349; 1,406) — typically indicates shares surrendered/withheld in connection with exercise or tax withholding.
- Shares owned after the transactions: Not specified in the provided filing excerpt.
- Relevant footnotes:
- F1: Includes 201 shares purchased under the company Employee Stock Purchase Plan (ESPP).
- F2–F4: Grant and vesting schedules for the referenced stock options (grants dated 2/14/2025; 2/16/2024; 4/4/2023 with multi-period vesting).
Context This filing shows an insider exercise of vested options paired with an open-market sale the same day. That pattern can reflect routine option-exercise and partial or full monetization (including share surrender/withholding to cover exercise costs or taxes). These entries are factual reports of transactions and do not, by themselves, indicate the insider’s view of the company’s prospects.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-05-15$56.69/sh+1,687$95,636→ 1,888 total - Exercise/Conversion
Common Stock
2026-05-15$49.23/sh+1,349$66,411→ 3,237 total - Exercise/Conversion
Common Stock
2026-05-15$17.97/sh+1,406$25,266→ 4,643 total - Sale
Common Stock
2026-05-15$92.21/sh−4,643$428,131→ 0 total - Exercise/Conversion
Stock Options (Right to Buy)
[F2]2026-05-15−1,687→ 3,713 totalExercise: $56.69Exp: 2035-02-13→ Common Stock (1,687 underlying) - Exercise/Conversion
Stock Options (Right to Buy)
[F3]2026-05-15−1,349→ 2,701 totalExercise: $49.23Exp: 2034-02-15→ Common Stock (1,349 underlying) - Exercise/Conversion
Stock Options (Right to Buy)
[F4]2026-05-15−1,406→ 2,325 totalExercise: $17.97Exp: 2033-04-03→ Common Stock (1,406 underlying)
Footnotes (4)
- [F1]Includes an aggregate of 201 shares of Common Stock purchased pursuant to the Rhythm Pharmaceuticals, Inc. Employee Stock Purchase Plan.
- [F2]The stock options were granted on February 14, 2025. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
- [F3]The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
- [F4]The stock options were granted on April 4, 2023. The options vest and become exercisable as to 25% of the total shares on March 20, 2024 and, thereafter, as to the remaining 75% of the total shares in twelve equal quarterly installments of 6.25% beginning June 20, 2024 and ending March 20, 2027, subject to the Reporting Person's continued service on each such vesting date.